JHVEPhoto/iStock Editorial via Getty Images
When Teva Pharmaceuticals (TEVA) broke below its $10 support line established in October 2020, selling accelerated. By Mid July, selling capitulated, ahead of Teva’s quarterly earnings. The firm also benefited…

Click here to view the original article.